Natural Killer Cells and Solid Tumors

Ana Stojanovic    Adelheid Cerwenka
Innate Immunity, German Cancer Research Center, Heidelberg, Germany

Introduction

With the exception of certain hematological malignancies, cellular transformation events often result in the formation of a solid primary tumor mass that can lead to metastases. The most frequent cancers in industrialized countries are solid tumors derived from epithelial tissues, such as breast, lung, prostate or colorectal carcinoma. The prognosis of patients suffering from these carcinomas is still very poor. Protocols for the treatment of solid tumors mostly rely on the surgical removal of the primary tumor mass. Advanced stages of cancer, however, preclude surgical resection. Reduction of the tumor mass is required, which is mainly achieved by irradiation or chemotherapy, both of which are characterized by severe side effects.

During tumor formation, malignant cells and infiltrating immune cells constantly interact with each other and shape the tumor microenvironment. In the majority of studies, high numbers of immune cells, such as natural killer (NK) cells or CD8⁺ T cells, infiltrating the tumors correlate with an improved prognosis for cancer patients [1, 2]. Thus, therapeutic strategies aiming at increasing the numbers of these cells in tumors might be beneficial.
to improve current immunotherapy protocols. NK cells were initially described as innate immune effector cells with the capacity to destroy tumor cells without prior sensitization [3, 4]. More recently, it has become clear that although resting NK cells mount certain responses [5], the activation of NK cells, such as by ‘priming’ with dendritic cells (DCs) [6], is required to exploit their full effector potential. The parallel inhibition of mechanisms counteracting NK cell activation should facilitate effective NK cell responses. A crucial role of NK cells in the elimination of hematological malignancies, tumor metastases and small tumors has been recognized [7, 8]. However, the NK cell-mediated response against established solid tumors at late stages of tumor progression remains largely ineffective.

**The Importance of NK Cells during Antitumor Immune Responses**

Individuals with impaired NK cell function, as assessed by the lysis of K562 cells, display an increased risk of developing cancer [9]. Moreover, studies in experimental tumor models demonstrated that NK cells were involved in the control of the certain tumors, including spontaneously arising, transplanted or carcinogen-induced malignancies. In the majority of these studies, NK cell depletion was performed with anti-NK1.1 or anti-asialo-GM1 mAbs. This experimental approach leaves the possibility that the depleting mAbs affected other cell populations, such as NKT or myeloid cells, as well. Several reports indicated that in mice deficient for activating NK cell receptors, such as NKG2D or NKP46, tumor growth was enhanced [10, 11]. Furthermore, increased levels of NKG2D ligands and NKP46 ligands were expressed by tumors arising in NKG2D- or NKP46-deficient mice, respectively [10, 12]. These results suggest that NKG2D and NKP46 are involved not only in tumor immune surveillance but also in immunoeediting and tumor escape. Accelerated tumor progression was also observed in mice lacking molecules involved in NK cell effector responses, including perforin, TRAIL and IFN-γ. However, these molecules are expressed not only by NK cells but also by other immune cells, and in most studies the relative contribution of NK cells remained poorly defined.

The report of selective expression of NKP46 by NK cells prompted the generation of improved tools for the investigation of NK cell responses [13]. Mice carrying the NKP46 promoter linked to the diphtheria toxin receptor were generated, in which most NK cells are depleted by diphtheria toxin application. Moreover, crossing mice carrying the NKP46 promoter linked to Cre recombinase with mice with loxP site-flanked genes resulted in mouse strains that allow the investigation of the deficiency of defined molecules in NKP46+ cells [14]. Importantly, NKP46 is more broadly expressed as previously anticipated. Recently, it was reported that NKP46 is expressed on lymphoid tissue inducer-like cells involved in the rejection of IL-12-transfected subcutaneously applied B16 melanoma [15]. This rejection was abrogated in mice lacking the transcription factor RORγt, but was functional in Rag1−, IL-15Rα−, IL-22−, IL-17α−, IFN-γ−, IFN-γR1− and perforin-deficient mice. Furthermore, a cell population in mouse intestinal mucosa, closely related to lymphoid tissue inducer cells, was recently described to express NKP46 [16]. These cells depend on RORγt, produce IL-22 and lack ‘natural cytotoxicity’ in vitro that is the typical feature of classical NK cells. Thus, certain NKP46-expressing subpopulations might have distinct developmental requirements and functional properties compared to classical NK cells.

So far, most studies investigating NK cell responses to tumors were performed in tumor models using transplanted tumor cell lines. In these models, inoculation of tumor cells exposes NK cells to nonphysiologically high numbers of malignant cells. Furthermore, transplanted tumor cell lines arose and/or were passaged in mice. Thus, these cell lines were shaped by the presence of the immune system and often acquired a low immunogenic phenotype to escape from immunosurveillance. In tumor models of transplanted tumor cells, the importance of NK cells for tumor rejection depends on the numbers of injected tumor cells. The MHC class I-deficient lymphoma cell line RMA-S is rejected when injected at relatively low cell numbers, whereas high cell numbers lead to continuous tumor growth. Depletion of NK1.1+ cells resulted in accelerated tumor growth indicating that tumor growth was controlled by NK1.1+ cells [17].

Mouse models of spontaneously arising tumors allow a more accurate analysis of the dynamics and kinetics of NK cell antitumor responses. In these models, NK cells face small numbers of transformed cells in the early phase of tumor development and tumor progression more closely resembles the development of solid human tumors. Although studies in mouse models of transplanted tumor cell lines provide insight into the general mechanisms of NK cell responses against tumors, it is important to validate novel results in mouse models of spontaneous tumor formation.

Stojanovic/Cerwenka
Examples of NK Cell-Based Immunotherapy

Currently, several approaches that exploit NK cells for antitumor therapy exist. Upon haploidentical stem cell transplantation of patients suffering from acute myeloid leukemia, >50% of patients who received grafts with donor-recipient killer immunoglobulin receptor (KIR)-HLA class I mismatch survived longer than 5 years as compared to <5% in the absence of the mismatch [18]. In vitro studies demonstrated that most acute myeloid leukemia blasts expressed ligands for the activating NK cell receptors DNAM-1, NKp30 and NKp46, and were susceptible to NK cell lysis [19]. Several treatments of solid tumors involve NK cells as well [20]. NK cells are implicated in the response to Mycobacterium bovis bacillus Calmette-Guerin treatment of bladder cancer and tyrosine kinase inhibitor imatinib mesylate (Gleevec) treatment of gastrointestinal stromal tumors. In addition, the efficiency of antibody-based therapy partially relies on NK cell-mediated antibody-dependent cellular cytotoxicity. NK cells were also recognized as effectors in DC-based immunotherapy. During antitumor immune responses, NK cells are an important source of IFN-γ that has multiple antitumor effector functions, including the inhibition of angiogenesis and tumor vascularization [21]. Importantly, regulatory functions of NK cells, such as the secretion of the immunosuppressive cytokine TGF-β, elimination of antigen-presenting cells and direct lysis of activated T cells [22], were also reported. Thus, protocols of cancer immunotherapy should consider possible adverse effects of NK cells in antitumor immunity.

NK Cell Accumulation in the Tumor Tissue

NK cells are detected in solid tumors in both mouse models and cancer patients. In lung, gastric or colorectal cancer patients, a high number of NK cells in the tumor tissue correlated with an improved prognosis [2, 23, 24]. In gastric carcinoma, high amounts of infiltrating NK cells correlated with the reduced depth of tumor invasion, lower numbers of metastases in the lymph nodes and improved clinical outcome. In these studies, NK cells were identified by the expression of CD57. CD57 defines only a subset of NK cells and comprises a small subpopulation of T cells as well. Recent studies demonstrated that CD57 was preferentially expressed by CD56^dim^NK cells and correlated with a high expression of inhibitory MHC class I-specific KIRs; low expression of the activating receptors NKp30, NKp46 and NKG2D; low expression of the cytokine receptors IL-2R and IL-12R; and reduced proliferative capacity [25, 26]. Moreover, CD57^+^NK cells were potent IFN-γ producers and showed high lytic capacity when stimulated via CD16. These observations suggest that tumor tissue infiltration by CD56^dim^CD57^+^NK cells might be beneficial for effective antitumor responses. It will be important to revisit these studies using markers expressed on all NK cells such as NKP46.

Several studies indicated that tumor tissues were preferentially infiltrated by CD56^bright^CD16^-^NK cells [27, 28]. Figure 1 illustrates several mechanisms that might contribute to the increased frequency of CD56^bright^CD16^-^NK cells in tumors. It is currently not known whether CD56^bright^ and CD56^dim^ subsets are differentially recruited to the tumor site and/or whether their phenotype...
is changed by the tumor microenvironment. Elevated numbers of CD56\textsuperscript{bright} NK cells in the tumor might be a consequence of their increased proliferation and/or survival. In this respect, it was demonstrated that CD56\textsuperscript{bright} NK cells display improved survival under conditions of oxidative stress, which is often present within tumor tissue [29].

In most cases, the frequency of NK cells among total tumor-infiltrating immune cells is low, resulting in a low ratio between NK cells and tumor cells. In addition, as reported for colon and lung cancer, NK cells are often not located in direct contact with tumor cells, but rather in the proximity of the blood vessels within the stroma [30, 31]. Application of IL-2, IL-12, IL-21, IFN-α, CpG or therapeutic mAbs, was shown to increase numbers and/or activity of peripheral blood NK cells in cancer patients [20]. Increased NK cell numbers in the blood might be beneficial for the elimination of hematological malignancies or disseminated tumor cells. However, based on the low overall response seen in most of the treated patients with solid tumors, we assume that efficient targeting of these tumors by NK cells should aim at an increase of their numbers and activation in the tumor tissue.

NK cells arrive at the tumor site via the blood, extravasate through vessels and migrate through the tumor tissue. These processes depend on molecules that mediate cell-cell and cell-extracellular matrix interactions, the modulation of extracellular matrix components and on chemokines and chemokine receptors expressed by NK cells [32]. Receptors that mediate NK cell migration to inflamed tissues such as CCR2, CCR5, CXCR3 and CX3CR1 allow NK cells to respond to a broad spectrum of inflammatory chemokines [33]. CXCR3 and CX3CR1 were implicated in NK cell recruitment to the tumor tissue. These receptors are differentially expressed by NK cell subsets. We observed that tumors of different origin injected subcutaneously in congenic mice were mainly infiltrated by the CD11b\textsuperscript{+}CD27\textsuperscript{high} NK cell subset [our unpubl. observations] that is considered to be the mouse equivalent of the human CD56\textsuperscript{bright} population. CD11b\textsuperscript{+}CD27\textsuperscript{high} NK cells express CXCR3 and are attracted to the tumor in a CXCR3-dependent manner [34]. Similarly, in humans, the CD56\textsuperscript{bright} NK cell subset expresses CXCR3 at high levels that might be responsible for their preferential accumulation in tumors. In vitro, mouse CD11b\textsuperscript{+}CD27\textsuperscript{high} NK cells display superior responses compared to the CD27\textsuperscript{low} subset [35]. However, the functional properties of human NK cell subpopulations are more complex. Traditionally, CD56\textsuperscript{dim} NK cells were classified as ‘killers’ whereas CD56\textsuperscript{bright} were considered as ‘cytokine producers’. More recent studies revealed that NK cell responses were dependent on the type of activation and that both subsets performed both functions when triggered appropriately [36]. In this respect, we assume that the activation stimuli and the tumor microenvironment determine the type of response exerted by tumor-infiltrating NK cells. To date, it is still not clear, which NK cell subpopulation is most effective in controlling tumor growth in vivo.

Several studies have investigated whether tumors that are susceptible to NK cell lysis were infiltrated by higher numbers of NK cells. More NK cells were shown to accumulate in the peritoneum of mice inoculated with MHC class I-deficient RMA-S compared to MHC class I-sufficient RMA cells [37]. Furthermore, higher numbers of NK cells were detected within NK cell-susceptible RMA-Rae-1 tumors as compared to NK cell-resistant RMA tumors [38]. These observations indicate that mouse NK cells preferentially accumulate in tumors susceptible to their lysis. However, in cancer patients different results were reported. For example, Sandel et al. [31] showed that although the majority of colorectal carcinoma displayed low or absent MHC class I expression and levels of immune cell infiltration were relatively high, attracted cells mostly resided in the tumor stroma. Loss of MHC class I on tumor cells positively correlated with CD8\textsuperscript{+} T cell infiltration and inversely correlated with NK cell infiltration in the tumors. These data would imply that certain tumors might selectively exclude cells that harm them. However, loss of MHC class I correlated with fewer metastases, suggesting that in those patients NK cells might be involved in the clearance of metastatic cells with diminished MHC class I expression [39].

**NK Cells within the Tumor Microenvironment**

Impaired effector functions of different immune cells isolated from tumor tissue were reported. Unresponsive tumor-specific T cells were isolated from various human tumors [40]. These cells can recover functional competence upon ex vivo stimulation, indicating that the process is reversible. The mechanisms underlying impaired T cell activation within the tumor include the alterations in the proximal TCR signaling machinery characterized by decreased expression of CD3ζ and the tyrosine kinases Lck and Fyn. Impaired expression of NF-κB family proteins correlates with decreased Th1 cytokine production and CTL function. In addition, conjugate formation of tumor-infiltrating CD8\textsuperscript{+} T cells with tumor...
cells ex vivo is impaired due to the defective expression and activation of adhesion molecules.

Several studies have investigated numbers and functionality of NK cells in tumor patients. In most studies, an impaired function of NK cells isolated from tumors was reported and an association of impaired NK cell activity and cancer progression was described [41, 42]. Figure 2 summarizes suppressive factors that inhibit NK cell activation in the tumors. Decreased NK cell responses have been detected in patients with lung and liver cancer as well as in melanoma, chronic myeloid and acute lymphoid and myeloid leukemia [43–47]. Another study reported that in patients with metastatic disease, cytotoxic responses of peripheral blood cells against K562 cells were reduced, whereas cancer patients without metastases mounted responses comparable to healthy donors [48].

In mouse models of subcutaneously injected melanoma, breast or colon carcinoma cells, NK cell differentiation to the final maturation stage in the bone marrow was impaired during the late stages of tumor progression leading to accumulation of immature NK cells [49]. In parallel, spleen NK cells from tumor-bearing mice did not show defects in cytotoxicity, whereas IFN-γ production was reduced in response to PMA/Ionomycin, but not to IL-12 stimulation. Recently, Brenner et al. [50] reported that in a transgenic mouse model of spontaneously arising lymphoma, effector functions of tumor-infiltrating NK cells became paralyzed during tumor progression.

Similar to T cells, different mechanisms account for the NK cell impairment in cancer patients. NK cells isolated from ascetic fluid of ovarian carcinoma patients expressed decreased levels of CD3ζ, FcεRIγ and Lck compared to cells from peripheral blood, which correlated with their reduced ability to produce IFN-γ upon IL-2 stimulation [51]. Tumor-infiltrating NK cells in ovarian cancer patients that expressed low levels of CD3ζ produced less IFN-γ, IL-2 and IL-4, but more IL-10, compared to peripheral blood NK cells [52]. Moreover, we observed that mRNA levels of several key components of the signaling machinery downstream of activating NK cell receptors, such as Lck, PI3K, PLCγ and Vav, were decreased in NK cells infiltrating mouse lymphoma compared to peripheral blood NK cells [our unpubl. observations].

In most studies that investigate NK cell function from cancer patients, NK cells are isolated from peripheral blood due to the good accessibility of blood samples and tested against targets such as K562. It has to be considered that peripheral blood NK cells might display many differences with regards to phenotype and function compared to NK cells isolated from the tumor tissue. To correlate NK cell responses after certain treatments with the prognosis of tumor patients, it is important (whenever possible) to investigate the effector potential of tumor-infiltrating NK cells rather than the potential of peripheral blood NK cells.

NK Cell-Mediated Target Recognition in the Tumor Microenvironment

Activating receptors expressed by NK cells, including NKG2D, NCRs and DNAM-1, have been implicated in direct recognition of cancer cells. The control of tumor growth mediated by the activating receptor NKG2D operates mainly through perforin-dependent cytotoxicity and can be enhanced by treatment with IL-2 and IL-12 [53]. NKG2D ligands are expressed on the surface of many tumor cell lines and primary tumor cells, but rarely by healthy cells [54]. Induction of NKG2D ligands via the activation of the DNA damage pathway by certain chemotherapeutic drugs or ionizing radiation can increase the visibility of tumors to NK cells [55]. Similarly, DNA damage pathway activation increases the expres-
sion of the poliovirus receptor CD155 and Nectin-2, ligands for activating receptor DNAM-1 [56]. Efficient recognition of target cells usually involves engagement of more than one activating receptor [57]. The simultaneous blockade of DNAM-1 and NCRs often leads to the complete abrogation of tumor cell lysis. Most NCR ligands expressed on tumor cells are still elusive. It was recently reported that Nkp30 binds to BAT3, an intracellular protein that is released upon cell death [58]. In addition, B7-H6, a novel member of the B7 protein family expressed by certain tumor cell lines and a subset of primary tumor cells of hematological neoplasias, but not by healthy cells, binds to Nkp30 and activates NK cell cytotoxicity [59].

The surface expression of activating NK cell receptors in cancer patients is often reduced on tumor-infiltrating compared to NK cells from peripheral blood [60]. In vitro studies indicated that fibroblasts derived from human melanoma interfered with NK cell cytotoxicity and cytokine production through the decrease of Nkp30, Nkp44 and DNAM-1 expression [61]. NKG2D cell surface expression was shown to be downregulated upon continuous exposure to its ligands, which also leads to the impaired function of several other activating NK cell receptors [62]. Similarly, DNAM-1 is downregulated upon NK cell exposure to target cells expressing cognate ligands [63]. In cancer patients, NKG2D ligands are often shed from the surface of tumor cells [64, 65]. Increased levels of soluble NKG2D ligands in serum correlated with the decreased expression of the NKG2D on both NK and CD4+ T cells. Moreover, elevated serum levels of soluble ULBP2 in melanoma patients were associated with disease progression and poor prognosis [66]. Soluble factors such as TGF-β and l-kynurenine, a tryptophan catabolite generated by indoleamine 2,3-dioxygenase, also downregulate NKG2D and Nkp30 cell surface expression by NK cells [67, 68]. Our unpublished data suggest that expression of activating NK cell receptors in the tumor microenvironment is also regulated at the transcriptional level and that receptors recognizing tumor cells are preferentially downregulated.

**Interplay of NK Cells with Other Immune Cells in the Tumor Tissue**

Within the tumor tissue, multiple cell types with suppressive functions can be detected, including immature DCs, macrophages polarized towards the immunoregulatory M2 phenotype, suppressive myeloid cells and regulatory T cells (Treg). The number of cytolytic NK and CD8+ T cells is low compared to cells that suppress immune responses and support tumor progression. In tumors, NK cells can interact with different types of immune cells affecting the function of both interaction partners. DCs in solid tumors often display an immature phenotype characterized by low expression of costimulatory molecules [69]. The cross-talk of NK cells with DCs leads to DC maturation, but under certain conditions results in the elimination of immature DCs [70]. Tumor-associated macrophages originating from blood monocytes accumulate in the tumor tissue and become reprogrammed in the tumor microenvironment to support tumor progression [71]. They secrete factors that recruit other myeloid cells, support angiogenesis and matrix remodeling, and polarize T cell differentiation towards Th2 and Treg IFN-γ produced by NK cells is a crucial factor to prevent macrophage polarization towards M2 phenotype and induce DC maturation. Thus, NK cells might affect several types of potentially immunosuppressive cells and thereby support the generation of efficient antitumor responses.

Several factors produced within the tumor tissue, such as VEGF, GM-CSF, M-CSF and IL-6, impede normal myelopoiesis and support accumulation of immature myeloid cells in the bone marrow, blood, spleen and tumor of tumor-bearing mice and cancer patients [72]. These cells can suppress T cell responses and were called ‘myeloid-derived suppressor cells’ (MDSCs). In mouse models, MDSCs were reported to suppress [73] or promote NK cell responses [74], depending on the tumor model studied. Evidence exists that NK cells eliminate the monocytic subset of MDSCs expressing the NKG2D ligand Rae-1 [74].

Similar to MDSCs, Treg accumulate in blood, draining lymph nodes and tumor tissue of cancer patients and tumor-bearing mice. Both active recruitment and in situ proliferation contribute to Treg accumulation and are mediated by other suppressive cells in tumors, such as immature DCs and MDSCs. Treg control homeostatic proliferation of NK cells in mice as well as their antitumor responses. Moreover, NK cell-mediated rejection of RMA-S-Rae-1β tumors is inhibited by Treg [75]. Further reports demonstrated that membrane-bound TGF-β was responsible for Treg-mediated downregulation of NKG2D and suppression of IL-12-induced IFN-γ production by NK cells [76].

In conclusion, a complex regulatory network of NK cells and other immune cells exists in the tumor tissue. Its therapeutic manipulation will contribute to efficient NK cell activation against tumors.
Effect of Tumor-Released Soluble Factors on NK Cell Function

Several characteristics of the tumor microenvironment impede effective antitumor immune responses. Low pH and oxygen concentration prevent the normal function of effector cells, including NK cells [77]. TGF-β is an important immunosuppressive factor with broad effects on both tumor and infiltrating immune cells [78]. It attenuates IL-2-induced IFN-γ production and lytic activity by NK cells and directly affects the expression of activating receptors. Furthermore, TGF-β can indirectly influence NK cell antitumor responses by affecting DC function, by inducing T_{reg} or modulating the expression of adhesion molecules by endothelial cells in tumor vessels. Within the tumor microenvironment, TGF-β exerts its function mainly by its membrane-bound form presented by T_{reg} and MDSCs [73, 76].

IL-10 is an important cytokine that can be secreted within the tumor tissue by tumor cells, macrophages, DCs, B cells and various subsets of CD4+ and CD8+ T cells, including T_{reg} [79]. IL-10 differentially affects the response of various immune cells. Evidence of both inhibitory and stimulating effects of IL-10 on NK cell target recognition have been reported. In animal tumor models, administration of the IL-10 recombinant protein or IL-10 gene therapy resulted in profound inhibition of tumor growth and metastases, and involvement of NK cells has been suggested [80]. IL-10 exerts a pleiotropic function on various immune cells and tumor cells, and its role in antitumor responses remains unclear.

Several additional soluble factors produced within the tumor microenvironment, including nonclassical HLA molecules (HLA-E, -F and -G) were shown to affect NK cell function [81]. HLA-G expression on malignant cells is controlled by epigenetic mechanisms, hypoxia and cytokines such as GM-CSF, IFN-γ, IL-10 and LIF. HLA-G can be transferred by trogocytosis from APCs and tumor cells to T cells and NK cells resulting in HLA-G+ T and NK cells with regulatory functions [82]. KIR2DL4 and ILT-2 (LIR-1), two NK cell receptors that mediate distinct responses, recognize HLA-G. Engagement of KIR2DL4 on NK cells by soluble HLA-G results in the induction of proinflammatory and proangiogenic responses [83], whereas HLA-G expressed on the surface of target cells binds to the receptor ILT-2 and leads to NK cell inhibition [84].

We conclude that multiple factors in the tumor microenvironment affect different aspects of NK cell function. Their manipulation might help to tip the delicate balance between NK cell activation and inhibition in favor of effective NK cell responses against tumors.

Conclusions

Although certain therapeutic approaches succeeded in increasing NK cell numbers in the peripheral blood of cancer patients and their ex vivo responses, only minor effects on tumor progression were observed [20]. The reasons might be low NK cell numbers detected in the tumor tissue and the distinct nature of tumor-infiltrating NK cells, including their subset distribution, phenotype, potential interactions with other immune cells and the overall influence of the tumor microenvironment on NK cell function. Therefore, additional knowledge has to be gained regarding NK cell recruitment into tumors, their effector functions within the tumor tissue and their regulation by the complex tumor microenvironment. In addition, further attention has to be devoted to the variety of different tumor entities, their differential sensitivity to immune responses and their distinct potential for immune evasion. Thus, profound knowledge about NK cells in tumors and the influence of the tumor microenvironment will open new promising avenues for the development of improved anticancer immunotherapeutic strategies.

Acknowledgements

We would like to thank Dr. Alexander Rölle for critically reading the manuscript. We would like to apologize to the authors of papers that could not be cited in this review because of space limitations.

References


NK Cells and Solid Tumors


45 Pierso BA, Miller JS: CD56-bright and CD56-dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996;88:2279–2287.


84 Favier B, Lemaoult J, Lesport E, Carosella ED: IILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J 2010;24:689–699.